Currently out of the existing stock ratings of Naureen Quibria, 16 are a BUY (94.12%), 1 are a HOLD (5.88%).

Naureen Quibria

Work Performance Price Targets & Ratings Chart

Analyst Naureen Quibria, carries an average stock price target met ratio of 6.25% that have a potential upside of 27.82% achieved within 114 days. Previously, Naureen Quibria worked at CAPITAL ONE, MAXIM GROUP.

Naureen Quibria’s has documented 32 price targets and ratings displayed on 8 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on IMMP, Immutep Ltd ADR at 17-May-2024.

Wall Street Analyst Naureen Quibria

Analyst best performing recommendations are on CMRX (CHIMERIX).
The best stock recommendation documented was for CMRX (CHIMERIX) at 9/7/2022. The price target of $7 was fulfilled within 910 days with a profit of $4.83 (222.58%) receiving and performance score of 2.45.
CRDF Cardiff Oncology AYLA Ayala Pharmaceuticals ONCR Oncorus CMRX Chimerix KZIA Kazia Therapeutics Ltd ADR ONCT Oncternal Therapeutics IMMP Immutep Ltd ADR CM Canadian Imperial Bank Of Commerce

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 15-Sep-2026

$9

$7.76 (625.81%)

14 days ago
(15-Sep-2026)

0/3 (0%)

$7.66 (571.64%)

Buy Since 28-Jun-2026

$4

$2.76 (222.58%)

$4

2 months 30 days ago
(30-Jun-2026)

0/2 (0%)

$2.7 (207.69%)

Buy Since 06-Sep-2024

$2

$0.76 (61.29%)

$8

3 months 26 days ago
(03-Jun-2026)

0/2 (0%)

$0.6 (42.86%)

Buy Since 14-Apr-2025

$6

$4.76 (383.87%)

$10

7 months 4 days ago
(25-Feb-2026)

0/3 (0%)

$4.09 (214.14%)

Buy Since 22-Oct-2020

$10

$8.76 (706.45%)

$13

1 years 1 months 23 days ago
(06-Aug-2025)

0/9 (0%)

$7.56 (309.84%)

Show more analysts

Please expand the browser size to see the chart

✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?